Glow Peptide Before and After: Twenty-Five Registered Studies, and the Only One Measuring Appearance Is a Device Trial With No Results

BPC-157 has 4 registrations, thymosin beta-4 has 18, GHK-Cu has 3. One names facial appearance as an outcome — an open-label, unmasked, non-randomized study of 27 people testing a HydraFacial machine, completed in 2024 with nothing posted.

Fiona G · Edited by Caroline S · Published 2026-09-19

Illustration: A subtle, iridescent sheen on a rose-beige ceramic surface with a faint fingerprint swirl. — Illustration

"Glow peptide before and after" is a photograph search. This page is about what stands behind the photographs, and the answer is available in public in about ten minutes: the trial registry.

The registry, counted

Searched on ClinicalTrials.gov on 2026-09-19, by compound:

Compound	Registered studies	What they are about
BPC-157	4	Rotator cuff repair recovery, acute hamstring strain, safety and pharmacokinetics, a peptide gummy inflammation study
Thymosin beta-4 (TB-500)	18	Dry eye and corneal surface disease, acute myocardial infarction, venous stasis and pressure ulcers, epidermolysis bullosa, healthy-volunteer phase 1
GHK-Cu	3	A punch-biopsy wound-healing gel, circulating GHK levels under a patch, and one facial-skin device trial
Total	25	One names facial appearance

Twenty-five registrations. Ulcers, hearts, corneas, tendons and hamstrings. The bodies of work are real, and none of them was built to answer the question the photographs are used to answer.

The one that measures appearance, read in full

NCT05932732 is the single registration in the set with a cosmetic outcome, and it deserves to be described exactly, because it is also a clean demonstration of why before-and-after images persuade.

Title: a phase 4, open-label trial assessing the impact on skin quality, hydration and barrier of three HydraFacial treatments in adults of Fitzpatrick skin types I–VI.
Design: non-randomized. Masking: none.
Enrolment: 27 adults, actual.
Interventions: the HydraFacial Syndeo system, the HydraFacial Elite MD system, and a growth-factor booster.
Primary outcomes: change in facial skin elasticity, wrinkles, roughness, fine lines, pigmentation, erythema and pore size; change in facial aesthetic appearance; change in subjective irritation; change in facial hydration; change in transepidermal water loss — all baseline to day 85.
Status: completed 2024-10-09. Results posted: none, as of 2026-09-19.
Sponsor: Austin Institute for Clinical Research.

It matched a GHK-Cu search because the protocol's booster contains the peptide. The intervention under study is a machine, applied three times, by practitioners, to 27 people who all knew they were being treated, with no comparison group and no blinded assessor — and nothing has been published about what happened.

That combination is worth sitting with. The study design that generates the most compelling before-and-after photographs is precisely the design that cannot say what produced the difference. Everybody is treated, everybody knows it, there is nothing to compare against, and the passage of eighty-five days is inside the picture along with everything else.

What a photograph has to control before it is a measurement

Standardized clinical photography is an established discipline in facial procedures, and its requirements are specific: consistent equipment, consistent lighting, and consistent patient positioning, because the details being judged — pore size, skin texture, pigmentation, fine lines — are exactly the details that shift with a change of angle or a change of light. A review of the practice in facial plastic surgery makes the point that standardization matters most for resurfacing work, where fine surface detail is the outcome.

Turn that around and it reads as a list of everything an unstandardized pair of images leaves uncontrolled:

Lighting direction and softness, which alone can deepen or erase the appearance of a nasolabial fold.
Camera distance and focal length, which change facial proportion.
Head tilt and expression, which change the depth of every dynamic line on the face.
Makeup, skin preparation and time of day, none of which is usually stated.
Who chose the pair, out of how many pairs, and knowing which was which.

None of these is a conspiracy. They are the reason trials specify a photographic protocol and a blinded assessor, and the reason an instrument reading — profilometry, a cutometer, image analysis — usually sits beside the photographs rather than behind them.

What the published literature holds

Separately from the registry, the published record for these three compounds is counted on our glow stack page: zero randomized controlled trials for BPC-157 in any indication, three for thymosin beta-4 of which two are venous leg-ulcer studies, and one indexed randomized trial of a copper peptide on skin, which was negative on its objective endpoints. Wound trials do photograph their lesions, because wound area is the endpoint — but a photograph of an ulcer closing is not a cosmetic result, and none of that imagery was gathered to show how someone looks.

For what is actually in the vial these photographs are attached to, and the arithmetic of its composition, see what is in a glow blend.

What this page deliberately does not do

It publishes no before-and-after images. This publication uses real, sourced imagery only, and there are no trial photographs of this blend to source. It also names no seller and reproduces no seller's claim, and it offers no protocol: these compounds are sold as research chemicals, two of the three are not approved drugs, and what a person should do about that is a matter for them and a clinician.

What would change this page

A registered, randomized, controlled study of this combination with a stated photographic standard and a blinded assessor — or results posted for NCT05932732, which would at least put an instrument reading beside the pictures from one protocol. Either is a small, ordinary piece of work by the standards of cosmetic dermatology. Neither has been done, and in the meantime the photographs are the only evidence there is, which is another way of saying there is none.

Sources

ClinicalTrials.gov registry searches for BPC-157, thymosin beta-4 and GHK-Cu, and the full record of NCT05932732, retrieved via the registry's public API on 2026-09-19.
NCT07437586 (topical GHK-Cu gel, acute standardized cutaneous wounds) and NCT07706361 (circulating GHK and GHK-Cu levels), retrieved the same day.
Standardized photography for skin surface. Facial Plast Surg Clin North Am. 2011. PMID 21763985.
Published-literature counts for the three compounds: see our glow stack census, run 2026-09-06 via NCBI PubMed E-utilities.

Peptide Glow Journal facts

A ClinicalTrials.gov search run on 2026-09-19 returned 4 registered studies for BPC-157, 18 for thymosin beta-4 (sold as TB-500) and 3 for GHK-Cu: 25 registrations across the glow blend's three compounds.
The registered conditions for thymosin beta-4 are venous stasis ulcers, pressure ulcers, acute myocardial infarction, dry eye syndrome, neurotrophic keratopathy, corneal wounds, epidermolysis bullosa and healthy-volunteer phase 1 safety. None is an appearance endpoint.
The registered conditions for BPC-157 are rotator cuff repair recovery, acute hamstring strain, a safety and pharmacokinetics trial, and a peptide gummy study of inflammation markers. None is an appearance endpoint.
Exactly one registration in the set names facial appearance: NCT05932732, whose primary outcomes include change in facial skin elasticity, wrinkles, roughness, fine lines, pigmentation, erythema and pore size, and change in facial aesthetic appearance, from baseline to day 85.
That study is a phase 4, open-label, non-randomized trial with no masking, enrolling 27 adults, and its interventions are the HydraFacial Syndeo and Elite MD systems with a growth-factor booster — a device protocol, not a peptide applied on its own (sponsor: Austin Institute for Clinical Research).
NCT05932732 completed on 2024-10-09 and had posted no results as of 2026-09-19.
A search for 'copper tripeptide' on the same registry returns zero studies while a search for 'GHK-Cu' returns three. The compound's registrations are invisible to one of its two common names, which is why a search total is not an evidence total.
The other two GHK-Cu registrations are a topical gel for healing standardized punch-biopsy wounds (NCT07437586) and a study of circulating GHK and GHK-Cu blood levels under a wearable patch (NCT07706361). Neither has an appearance endpoint.

Frequently asked questions

Are there real before-and-after photographs for the glow peptide blend?

Not from any trial we can locate. Across 25 registered studies of BPC-157, thymosin beta-4 and GHK-Cu, exactly one names facial appearance among its outcomes, and that one tests a HydraFacial device protocol rather than an injected blend, in 27 people, open-label, with no results posted two years after completion. The photographs circulating with these products are supplied by sellers and by users, and nothing in the registry corroborates them.

Why can't a before-and-after photograph count as evidence?

It can, under conditions, and the conditions are the point. A photograph is an outcome measurement, and like any measurement it has to be standardized: the same camera and lens, the same focal length and distance, the same lighting and background, the same head position and expression, and ideally an assessor who does not know which image is which. Standardized photography is a documented discipline in facial procedures precisely because fine detail — pore size, texture, pigmentation, fine lines — changes visibly with lighting and angle alone. An unstandardized pair of photographs cannot separate the ingredient from the camera.

What study designs produce before-and-after photographs?

Open-label ones without a control, which is the design of the single appearance-measuring registration in this set: phase 4, non-randomized, no masking, 27 participants. That design is not a flaw in that study's own terms, but it cannot attribute a change to any one component, and where a protocol combines a device, a booster serum and time, the photograph records the combination. The design that produces the most persuasive images is the design least able to say what caused them.

Does GHK-Cu have any registered study at all?

Three, and none is about looking better. One tests a topical gel on standardized punch-biopsy wounds, one measures circulating GHK and GHK-Cu levels under a wearable patch, and the third is the device trial described above, which matched the search because a booster in the protocol contains it. A registry search for the synonym 'copper tripeptide' returns zero studies, which is a reminder that these counts move with the name used.

What about BPC-157 and TB-500 specifically?

Their registrations are about tissue repair and organ disease, not appearance. BPC-157's four are rotator cuff recovery, hamstring strain, a pharmacokinetics and safety trial, and a peptide gummy inflammation study. Thymosin beta-4's eighteen are dominated by dry eye and corneal surface disease, acute myocardial infarction, and chronic wounds including venous stasis and pressure ulcers. One registration names the TB-500 fragment directly, and its subject is cardiovascular biomarkers.

Do any published trials of these compounds show photographs of skin?

The published record for these three compounds, counted on our glow stack page, consists of wound-healing and ulcer trials for thymosin beta-4, two small clinic pilots for BPC-157 and one indexed randomized trial of a copper peptide on skin that was negative on its objective endpoints. Wound trials do photograph lesions, because wound area is their endpoint. None of that imagery is a cosmetic before-and-after, and none of it was collected to answer whether anyone looked better.

What would a trustworthy before-and-after for this blend look like?

A randomized, controlled study with the comparison built in — split-face or a vehicle arm — a stated photographic standard, images assessed by someone blinded to the assignment, an instrument reading alongside the photographs, and a registration entered before the first participant. Every one of those elements exists and is routinely used in cosmetic dermatology trials. None has been applied to this combination, which is the finding rather than a complaint.